Brean Capital assumes coverage of Nektar Therapeutics (NASDAQ: NKTR ) with Buy rating and $23 price target on strong growth in royalties from recent and future new launches. "In our view, Nektar's ...
- Bloomberg•3 days ago
The Chan Zuckerberg Initiative, Facebook Inc. founder Mark Zuckerberg’s $3 billion effort to find cures for diseases, hired AstraZeneca Plc board member Cornelia Bargmann as president of its science arm....
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
|Bid||4,940.00 x 6100|
|Ask||5,060.00 x 13000|
|Day's Range||4,947.00 - 5,090.89|
|52wk Range||3,680.00 - 5,505.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||28.59|
|Avg Vol (3m)||2,589,384|
|Dividend & Yield||N/A (N/A)|